Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic Review Report; SR0356. 2014 Authors' conclusions The ICURs of sofosbuvir versus appropriate comparators varied widely across genotypes and various subgroups. Analyses in genotype 1 patients were limited by lack of direct comparative data. Most of the analyses in genotype 2 and genotype 3 patients were limited by the small sample size of the clinical trials used to inform efficacy inputs. Based on CDR reanalyses, sofosbuvir is likely cost-effective in the following subgroups: genotype 1 treatment-naive cirrhotic patients (compared with boceprevir and Peg-INF/RBV, but analyses were based on very small subgroups, and on a naive indirect treatment comparison); genotype 2 Peg-INF/RBV-ineligible and prior-relapsers or breakthrough (except cirrhotic patients) compared with no treatment and Peg-INF/RBV; genotype 3 prior-relapsers or breakthrough with cirrhosis, compared with no treatment and Peg-INF/RBV. Indexing Status Subject indexing assigned by CRD MeSH Antiviral Agents; Hepatitis C, Chronic; Humans; Uridine Monophosphate Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000162 Date abstract record published 04/03/2015 |
